Marc de Garidel, Chairman and Chief Executive Officer of Ipsen stated: "We are delighted to expand and deepen our collaboration with Galderma, based on our common ambition to
The terms of the placement are for the purchase of common shares at $1.60 per share and include one warrant per share at an exercise price of $2.24
Actavis’ ANDA product is a generic version of Duchesnay Inc.’s Diclegis, which is indicated for the treatment of nausea and vomiting of pregnancy in women who do not
With these latest grants, BrightFocus has now provided more than $8.7 million in research funding in 2014. The research projects funded this year reflect a range of study
The Geo Well Fermentation facility (GWF) is an underground earth-vessel based technology that will produce microbial products with a number of advantages. Primarily, the capital investment involved is
This follows the previously disclosed proteins already scheduled for production at PBP, namely plasminogen, IVIG and Alpha-1 Antitrypsin. Sales of fibrinogen manufactured at commercial scale to pharmaceutical companies
The application includes composition of matter claims on broad families of melanocortin receptor-1 specific peptides with potential utility for treatment of inflammatory diseases and disorders. The melanocortin-1 receptor
Numerous challenges limit the pace of progress for global clinical research. According to ACRES, the industry squanders $20 billion annually due to inefficiencies inherent to the current process
The expansion into aesthetic and corrective dermatology in the U.S. and Canada completes Galderma’s global skin health footprint and extends its leadership in aesthetic medicine worldwide. "We at
Treatment for advanced ovarian carcinoma is typically based on the combination of surgery and chemotherapy. The objective of surgical intervention in patients suffering from advanced disease is to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.